New York, USA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- 40+ Key Companies Actively Working in the Marginal Zone Lymphoma Pipeline Segment | DelveInsight
Marginal Zone Lymphoma Pipeline constitutes 40+ key companies continuously working towards developing 50+ Marginal Zone Lymphoma treatment therapies, analyzes DelveInsight
DelveInsight’s 'Marginal Zone Lymphoma Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline marginal zone lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the marginal zone lymphoma pipeline domain.
Key Takeaways from the Marginal Zone Lymphoma Pipeline Report
- DelveInsight’s marginal zone lymphoma pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for marginal zone lymphoma treatment.
- Key marginal zone lymphoma companies such as Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc, Celldex Therapeutics, TG Therapeutics, VelosBio Inc., Newave Pharmaceutical Inc, Boryung Pharmaceutical Co., Ltd, Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc., Gamida Cell, BeiGene, Loxo Oncology, and others are evaluating novel marginal zone lymphoma drugs candidate to improve the treatment landscape.
- Promising marginal zone lymphoma pipeline therapies in various stages of development include Tafasitamab, Orelabrutinib, EO2463, MIL62, Loncastuximab, NX-2127, LP-168, Zandelisib, BR101801, BP1002, Mosunetuzumab, CLR 131, IBI376, Pirtobrutinib, Zilovertamab vedotin, TG-1801, VAY736, ADI-001, CDX-1140, PSB202, Acalabrutinib, axicabtagene ciloleucel, Obinutuzumab, Cirmtuzumab, Nemtabrutinib, Lenalidomide, IGM-2323, Epcoritamab, GDA-201, BGB-16673, LOXO-305, and others.
- In August 2022, Gamida Cell announced dosing of the first patient in a company-sponsored Phase I/II study evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular, diffuse large B cell lymphomas and marginal zone lymphoma or mantle cell lymphoma.
- In August 2022, Orelabrutinib’s supplemental New Drug Application (sNDA) was accepted by the China National Medical Products Administration (NMPA) for the treatment of patients with relapsed or refractory Marginal Zone Lymphoma (R/R MZL).
- In June 2022, ADC Therapeutics announced the first patient has been dosed in LOTIS-7, a Phase 1b clinical trial evaluating ZYNLONTA in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The first arm of the LOTIS-7 open-label, multi-center, multi-arm Phase Ib trial will evaluate the safety and activity of ZYNLONTA in combination with polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, high grade B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Burkitt lymphoma.
- In May 2022, Oncternal Therapeutics announced that the CIRLL clinical trial (CIRM-0001) is a Phase I/II trial evaluating zilovertamab in combination with ibrutinib in separate groups of patients with CLL or MCL. Enrollment of the dose-finding cohorts in CLL and MCL, dose-expansion cohort in CLL and MCL and randomized Phase II cohort in CLL has been completed. An additional dose-expansion cohort of up to 10 patients with marginal zone lymphoma (MZL) has recently been added. Enrollment is expected to begin in Q2 2022.
Request a sample and discover the recent advances in marginal zone lymphoma treatment drugs @Marginal Zone Lymphoma Pipeline Outlook
The marginal zone lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage marginal zone lymphoma products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the marginal zone lymphoma pipeline landscape.
Marginal Zone Lymphoma Overview
MZL is the second most common indolent non-Hodgkin lymphoma (iNHL). Extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT or gastric GALT), splenic MZL, and nodal MZL are the three types of marginal zone lymphomas. EMZL can develop at almost any extranodal site and in organs that do not usually have lymphoid tissue (e.g., stomach, intestine, thyroid, lung, and skin). The stomach is the most commonly affected organ in EMZL, and there is compelling evidence linking H. pylori to gastric EMZL. SMZL is primarily caused by marginal zone memory B-cells found in splenic follicles, splenic hilar lymph nodes, BM, and peripheral blood. The exact marginal zone lymphoma causes are still not known.
The marginal zone lymphoma symptoms vary depending on the type. The most common marginal zone lymphoma symptoms include night sweats, skin rash, nausea, vomiting, stomach pain, indigestion, and others. Several tests, such as X-rays, ultrasound, CT scans, and MRI scans, are used for marginal zone lymphoma diagnosis.
Find out more about marginal zone lymphoma guidelines @Marginal Zone Lymphoma Treatment Guidelines
A snapshot of the Marginal Zone Lymphoma Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Orelabrutinib | InnoCare Pharma | Pre-registration | Agammaglobulinaemia tyrosine kinase inhibitors | Oral |
| Tafasitamab | Incyte Corporation | Phase III | Antibody-dependent cell cytotoxicity; T lymphocyte stimulants | Intravenous |
| MIL62 | Beijing Mabworks Biotech Co. | Phase III | Antibody-dependent cell cytotoxicity | Intravenous |
| Zandelisib | MEI Pharma, Inc./Kyowa Kirin | Phase III | Phosphatidylinositol 3 kinase delta inhibitors | Oral |
| Loncastuximab | ADC Therapeutics | Phase II | Alkylating agents; DNA cross-linking agents | Intravenous |
| LOXO-305 | Loxo Oncology | Phase II | Agammaglobulinaemia tyrosine kinase inhibitors | Oral |
| ADI-001 | Adicet Bio | Phase I | Immunologic cytotoxicity; T lymphocyte replacements | NA |
| CDX-1140 | Celldex Therapeutics Inc | Phase I | CD40 antigen stimulants; T lymphocyte stimulants | Intravenous |
Learn more about the emerging marginal zone lymphoma pipeline therapies @Marginal Zone Lymphoma Clinical Trials
Marginal Zone Lymphoma Therapeutics Assessment
The marginal zone lymphoma pipeline report proffers an integral view of the marginal zone lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Marginal Zone Lymphoma Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Inhalation, Intranasal, Intravenous, Subcutaneous, Parenteral
- Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, Vaccine
- Therapeutics Assessment By Mechanism of Action: Antibody-dependent cell cytotoxicity, T lymphocyte stimulants, Phosphatidylinositol 3 kinase delta inhibitors, Agammaglobulinaemia tyrosine kinase inhibitors, Alkylating agents, DNA cross linking agents, CD40 antigen stimulants, Immunologic cytotoxicity
- Key Marginal Zone Lymphoma Companies: Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc, Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc, Boryung Pharmaceutical Co., Ltd, Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc., and others
- Key Marginal Zone Lymphoma Pipeline Therapies: Tafasitamab, Amdizalisib (HMPL-689), Orelabrutinib, EO2463, MIL62, Loncastuximab, NX-2127, LP-168, Zandelisib, BR101801, BP1002, Mosunetuzumab, CLR 131, IBI376, Pirtobrutinib, Zilovertamab vedotin, TG-1801, VAY736, ADI-001, CDX-1140, PSB202, Acalabrutinib, axicabtagene ciloleucel, Obinutuzumab, Cirmtuzumab, Nemtabrutinib, Lenalidomide, IGM-2323, Epcoritamab, and others.
Dive deep into rich insights for drugs for marginal zone lymphoma treatment, visit @Marginal Zone Lymphoma Treatment Drugs
Table of Contents
| 1. | Marginal Zone Lymphoma Pipeline Report Introduction |
| 2. | Marginal Zone Lymphoma Pipeline Report Executive Summary |
| 3. | Marginal Zone Lymphoma Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Marginal Zone Lymphoma Pipeline Therapeutics |
| 6. | Marginal Zone Lymphoma Pipeline: Late Stage Products (Pre-registration) |
| 6.1 | Orelabrutinib: InnoCare Pharma |
| 7. | Marginal Zone Lymphoma Pipeline: Late Stage Products (Phase III) |
| 7.1 | Tafasitamab: Incyte Corporation |
| 8. | Marginal Zone Lymphoma Pipeline: Mid Stage Products (Phase II) |
| 8.1 | LOXO-305: Loxo Oncology |
| 9. | Marginal Zone Lymphoma Pipeline: Early Stage Products (Phase I) |
| 9.1 | ADI-001: Adicet Bio |
| 10. | Marginal Zone Lymphoma Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Marginal Zone Lymphoma Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Marginal Zone Lymphoma Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the marginal zone lymphoma pipeline therapeutics, reach out @Marginal Zone Lymphoma Drugs
Related Reports
Marginal Zone Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key marginal zone lymphoma companies, including Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., among others.
Non-Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key non-hodgkin’s lymphoma companies, including Roche, Amgen, Johnson & Johnson, Novartis, among others.
Non-Hodgkin’s Lymphoma Pipeline
Non-Hodgkin’s Lymphoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key non-hodgkin’s lymphoma companies, including Roche, Amgen, Johnson & Johnson, Novartis, among others.
Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Hodgkin lymphoma companies, including 4SC, ACD Therapeutics, TG Therapeutics, among others.
Hodgkin Lymphoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Hodgkin lymphoma companies, including 4SC, ACD Therapeutics, TG Therapeutics, among others.
Cutaneous T-cell Lymphoma Pipeline
Cutaneous T-cell Lymphoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key cutaneous T-cell lymphoma companies, including Wellness Pharma, Seagen, Soligenix, 4SC AG, among others.
Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key follicular lymphoma companies, including Merck, Genentech, Novartis, Janssen, among others.
Follicular Lymphoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key follicular lymphoma companies, including Merck, Genentech, Novartis, Janssen, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | CAR-T Pipeline Insight | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Outlook Report | Crows Feet Market Insight | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market
Related Healthcare Blogs
Emerging Oncological Drugs in 2022
Cutaneous T-cell Lymphoma Market Scenario
Follicular Lymphoma Treatment Market
Follicular Lymphoma Pipeline Landscape
CAR T-cell Therapy for Non-Hodgkin Lymphoma
Related Conferences
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
